EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sinopharm Tech Holdings Ltd (8156) fair value: what the stock is really worth

We calculate from audited financials what Sinopharm Tech Holdings Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Sep 13, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Technology · HK · ISIN KYG2159V1418

ST Thin data Sep 13, 2026

Sinopharm Tech Holdings Ltd

8156 · HK

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value HK$0.5049 · Strongly undervalued (+155%)
!Quality 43/100
!Weak Growth (revenue 5y −18.1 %/yr)
!Thin margins · 1.4% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Mixed vs. peers (4/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Sinopharm Tech Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$7.25 HK$0.0710 Fair Value HK$0.5049 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range HK$0.0710 – HK$7.25 · fair‑value band HK$0.3607 – HK$0.6221 · the HK$0.1980 price screens below the HK$0.5049 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Follow Sinopharm Tech Holdings in your weekly email

Every Wednesday you see whether Sinopharm Tech Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sinopharm Tech Holdings Limited, an investment holding company, engages in trading of medical and related products in China. It is involved in the provision of Internet plus solution services, including provision of internet related solution services; and manufacturing and distribution of personal protective equipment, consumables, and other related goods.

Show more

Sinopharm Tech Holdings Limited, an investment holding company, engages in trading of medical and related products in China. It is involved in the provision of Internet plus solution services, including provision of internet related solution services; and manufacturing and distribution of personal protective equipment, consumables, and other related goods. The company also engages in providing supply chain services, including provision of supply chain management, data analysis, and related services; and trading of related goods, and trading of medial and related products. Sinopharm Tech Holdings Limited was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. The company was founded in 1999 and is based in Central, Hong Kong.

Stock analysis

Sinopharm Tech Holdings Ltd (8156) currently trades at HK$0.1980, while our model-based Fair Value estimate is HK$0.5049, implying the stock looks roughly 60.8% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: HK$0.3607 (bear) to HK$0.6221 (bull), the price of HK$0.1980 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Technology sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Sinopharm Tech Holdings Ltd reported revenue of HK$61.3M in FY2025 versus HK$77.8M in FY2021, a compound −5.8%/yr. Reported net income was −HK$867K in FY2025.

Key figures

Market cap HK$129M (≈ $16.4M) · P/E ratio 19.8 · P/S ratio 1.86 · EPS (TTM) HK$0.0100 · Net margin −1.4% · Return on assets (EBIT) −84.4% · Operating margin −5.8% · Revenue (TTM) HK$69.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at −6% fair-value upside, at 155%, 8156 screens cheaper than that median.

Notify me when 8156 reaches fair value

Put 8156 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 44 · Market factors (momentum, volatility) 14

Profitability 39
Margins and returns on capital today
Quality Growth 86
Are margins and returns improving?
Cashflow 50
Earnings quality: real cash, not paper profit
Fin. Strength 15
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 4
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 18
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+48.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.1%
Start year 2020 (pandemic). Over 10 years: −6.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.6% (2020) → −11.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 8156, get fair value alerts →

Compare Sinopharm Tech Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 721 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside +155% · Top 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −10% · Bottom 25%
Net margin (TTM) 1% · Below median
Operating margin (TTM) −6% · Below median
Growth and dividend
Revenue growth 42% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Software - Application median · lower = cheaper

P/E (TTM) 19.8× · Cheaper than median
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.24× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 25
FUTURE (revenue growth)100 · sector 38
PAST (return on equity)0 · sector 16
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 30

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Software - Application stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
SAP SE SAP €184.18 €172.46 −6%
Salesforce, Inc CRM $238.22 $342.73 +44%
Shopify Inc SHOP $145.16 $64.36 −56%
ServiceNow, Inc NOW $137.78 $151.56 +10%
Uber Technologies, Inc UBER $69.22 $103.69 +50%
Cadence Design Systems, Inc CDNS $309.09 $225.14 −27%
Snowflake Inc SNOW $334.81 $75.08 −78%
Datadog, Inc DDOG $251.49 $32.92 −87%
Adobe Inc ADBE $238.25 $454.04 +91%
Automatic Data Processing, Inc ADP $263.68 $177.51 −33%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinopharm Tech Holdings Ltd · Fair Value
HK$0.5049 +61%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sinopharm Tech Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8156

Frequently asked questions

Is Sinopharm Tech Holdings Ltd (8156) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of HK$0.5049 versus a price of HK$0.1980, about +155% upside (undervalued).
What is the fair value of 8156?
Our model-based fair value for Sinopharm Tech Holdings Ltd is HK$0.5049 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$0.1980.
What is the quality score of 8156?
Sinopharm Tech Holdings Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinopharm Tech Holdings Ltd (8156)?
Our model-based price target is the fair value of HK$0.5049 (as of Sep 13, 2026) from 2 valuation models. Cautious scenario HK$0.3607, optimistic scenario HK$0.6221. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinopharm Tech Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.5049, about +155% upside versus a price of HK$0.1980 (undervalued). Cautious scenario HK$0.3607, optimistic scenario HK$0.6221. The calculation is refreshed regularly with new filings.
What is the revenue of Sinopharm Tech Holdings Ltd (8156)?
Sinopharm Tech Holdings Ltd reported trailing-twelve-month revenue of about HK$69.1M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Sinopharm Tech Holdings Ltd (8156)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinopharm Tech Holdings Ltd it is HK$0.5049 per share (as of Sep 13, 2026), against a price of HK$0.1980. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Sinopharm Tech Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 8156 trades below its calculated fair value: price HK$0.1980, fair value HK$0.5049, a gap of about +155% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8156?
No. The price is what the market pays today (HK$0.1980); the fair value is what the company's own numbers justify (HK$0.5049). For Sinopharm Tech Holdings Ltd the two are HK$0.3069 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinopharm Tech Holdings Ltd worth?
The market values Sinopharm Tech Holdings Ltd at about HK$129M (market capitalisation, as of Sep 13, 2026). Per share that is HK$0.1980; our models calculate a fair value of HK$0.5049 per share.
What do the bullish and bearish scenarios say about 8156?
Our models span a range for Sinopharm Tech Holdings Ltd: cautious scenario HK$0.3607, base HK$0.5049, optimistic HK$0.6221 per share (as of Sep 13, 2026, price HK$0.1980). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 8156?
Sinopharm Tech Holdings Ltd trades at a price-to-earnings ratio of 19.8 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.5049 is built from several models across several years. Other multiples: P/S 0.2.
How solid is the balance sheet of Sinopharm Tech Holdings Ltd (8156)?
Balance-sheet figures for Sinopharm Tech Holdings Ltd (as of Sep 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 8156 from its 52-week high?
Sinopharm Tech Holdings Ltd trades at HK$0.1980, about 43% below its 52-week high of HK$0.3500 and 29% above the low of HK$0.1530 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5049 is for.
Which stocks are comparable to Sinopharm Tech Holdings Ltd?
From the same area (Technology) we also value SAP SE, Salesforce, Inc, Shopify Inc, ServiceNow, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinopharm Tech Holdings Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price HK$0.1980, calculated fair value HK$0.5049 (+155%), Quality Score 43/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8156 calculated?
We run Sinopharm Tech Holdings Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.5049, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Sinopharm Tech Holdings Ltd currently trades 155 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinopharm Tech Holdings Ltd (8156)?
The closing price on Sep 24, 2026 was HK$0.1980. Our model-based fair value is HK$0.5049, about +155% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinopharm Tech Holdings Ltd right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$0.3607). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Sinopharm Tech Holdings Ltd

How large is the market capitalisation of Sinopharm Tech Holdings Ltd (8156)?
The market capitalisation of Sinopharm Tech Holdings Ltd is HK$129M (≈ $16.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinopharm Tech Holdings Ltd (8156)?
The price-to-sales ratio of Sinopharm Tech Holdings Ltd is 1.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinopharm Tech Holdings Ltd (8156)?
Earnings per share at Sinopharm Tech Holdings Ltd are HK$0.0100 (price ÷ EPS = P/E 19.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sinopharm Tech Holdings Ltd (8156)?
The net margin of Sinopharm Tech Holdings Ltd is −1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Sinopharm Tech Holdings Ltd (8156)?
On an EBIT basis the return on assets of Sinopharm Tech Holdings Ltd is −84.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinopharm Tech Holdings Ltd (8156)?
The operating margin of Sinopharm Tech Holdings Ltd is −5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinopharm Tech Holdings Ltd (8156)?
Revenue at Sinopharm Tech Holdings Ltd is growing +41.7% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sinopharm Tech Holdings Ltd (8156) generate?
The free cash flow of Sinopharm Tech Holdings Ltd is −HK$7.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sinopharm Tech Holdings Ltd (8156) carry?
The net debt of Sinopharm Tech Holdings Ltd is HK$39.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sinopharm Tech Holdings Ltd in the live analysis

One click puts Sinopharm Tech Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.